We claim:

1. An isolated antibody that binds PHF-tau comprising an antigen-binding site of a heavy chain variable region (VH) of SEQ ID NO:35 or 37, and an antigen-binding site of a light chain variable region (VL) of SEQ ID NO:36 or 38.
2. The isolated antibody of claim 1, wherein the antigen-binding site of the VH comprises heavy chain complementarity determining regions (CDRs) 1 (HCDR1), 2 (HCDR2) and 3 (HCDR3) of SEQ ID NOs:7, 8 and 9 or SEQ ID NOs:13, 14 and 15, respectively, and the antigen-binding site of the VL comprises light chain CDRs 1 (LCDR1), 2 (LCDR2) and 3 (LCDR3) of SEQ ID NOs:10, 11 and 12 or SEQ ID NOs: 16, 17 and 18, respectively.
3. The isolated antibody of any one of claim 1 or 2 that binds PHF-tau comprising an antigen-binding site of a VH of SEQ ID NO:35 and an antigen-binding site of a VL of SEQ ID NO:36.
4. The isolated antibody of claim 3, wherein the antigen-binding site of the VH comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:7, 8 and 9, respectively, and the antigen-binding site of the VL comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:10, 11 and 12, respectively.
5. The isolated antibody of any one of claim 1 or 2 that binds PHF-tau comprising an antigen-binding site of a VH of SEQ ID NO:37 and an antigen-binding site of a VL of SEQ ID NO: 38.
6. The isolated antibody of claim 5, wherein the antigen-binding site of the VH comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:13, 14 and 15, respectively, and the antigen-binding site of the VL comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:16, 17 and 18, respectively.
7. The isolated antibody of any one of claims 1-6, wherein the antibody is humanized.
8. An isolated antibody or fragment that competes for PHF-tau binding with a monoclonal antibody comprising an antigen-binding site of a VH of SEQ ID NO:35 and an antigen-binding site of a VL of SEQ ID NO:36, or an antigen-binding site of a VH of SEQ ID NO:37 and an antigen-binding site of a VL of SEQ ID NO:38.
9. An isolated polynucleotide encoding an antibody VH comprising HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:7, 8 and 9, respectively, or SEQ ID NOs:13, 14 and 15, respectively.

10. An isolated polynucleotide encoding an antibody VL comprising LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:10, 11 and 12, respectively, or SEQ ID NOs:16, 17 and 18, respectively.
11. A vector comprising a polynucleotide of claim 9 or 10.
12. A host cell comprising the vector of claim 11.
13. A method of making an antibody that binds PHF-tau comprising culturing the host cell of claim 12 and recovering the antibody produced by the host cell.

We claim:

1. An isolated antibody that binds PHF-tau comprising an antigen-binding site of a heavy chain variable region (VH) of SEQ ID NO:35 or 37, and an antigen-binding site of a light chain variable region (VL) of SEQ ID NO:36 or 38.

2. An isolated antibody that binds PHF-tau, wherein the antigen-binding site of the VH comprises heavy chain complementarity determining regions (CDRs) 1 (HCDR1), 2 (HCDR2) and 3 (HCDR3) of SEQ ID NOs:7, 8 and 9 or SEQ ID NOs:13, 14 and 15, respectively, and the antigen-binding site of the VL comprises light chain CDRs 1 (LCDR1), 2 (LCDR2) and 3 (LCDR3) of SEQ ID NOs:10, 11 and 12 or SEQ ID NOs: 16, 17 and 18, respectively.

3. The isolated antibody of claim 1 that binds PHF-tau comprising an antigen-binding site of a VH of SEQ ID NO:35 and an antigen-binding site of a VL of SEQ ID NO:36.

4. The isolated antibody of claim 2, wherein the antigen-binding site of the VH comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:7, 8 and 9, respectively, and the antigen-binding site of the VL comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:10, 11 and 12, respectively.

5. The isolated antibody of claim 1 that binds PHF-tau comprising an antigen-binding site of a VH of SEQ ID NO:37 and an antigen-binding site of a VL of SEQ ID NO: 38.

6. The isolated antibody of claim 2, wherein the antigen-binding site of the VH comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:13, 14 and 15, respectively, and the antigen-binding site of the VL comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:16, 17 and 18, respectively.

7. The isolated antibody of any one of claims 1-6, wherein the antibody is humanized.

8. An isolated polynucleotide encoding an antibody VH comprising HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:7, 8 and 9, respectively, or SEQ ID NOs:13, 14 and 15, respectively.

9. An isolated polynucleotide encoding an antibody VL comprising LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:10, 11 and 12, respectively, or SEQ ID NOs:16, 17 and 18, respectively.

10. A vector comprising a polynucleotide of claim 8 or 9.

11. A host cell comprising the vector of claim 10.